NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Bo Hedlund, PhD

Practice Area Focus

  • Drugs
  • Biologics
  • Diagnostics
  • Generics
  • CMC
  • Preclinical Study Design
  • Development Strategy
  • Clinical Pharmacology
  • Drug Safety
  • Toxicology


Bo Hedlund, PhD, joined NDA Partners as an Expert Consultant in 2017. He is currently an Adjunct Professor of Medicine at the University of Minnesota Medical School.

During his academic career at the University, Dr. Hedlund conducted research on hemoglobin chemistry and the role of iron in biology and medicine. He subsequently left the University to become President and CEO of Biomedical Frontiers, Inc., a start-up drug development company he co-founded. In this capacity he was responsible for initial patent applications and supervised pre-clinical and clinical submissions for a novel iron binding drug. This drug technology may have several applications in areas of hematology.

Dr. Hedlund is a Distinguished Emeritus Member of the American Society of Hematology. He has served, over the last decade, as an external reviewer of SBIR applications submitted to the National Heart, Lung and, Blood Institute (NHLBI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).